4//SEC Filing
Sucampo Pharmaceuticals, Inc. 4
Accession 0001209191-14-051232
CIK 0001365216operating
Filed
Aug 6, 8:00 PM ET
Accepted
Aug 7, 6:00 PM ET
Size
11.7 KB
Accession
0001209191-14-051232
Insider Transaction Report
Form 4
Kuno Sachiko
Director10% Owner
Transactions
- Sale
Class A Common Stock
2014-08-05$6.24/sh−84,243$525,744→ 22,558,286 total(indirect: By LLC) - Sale
Class A Common Stock
2014-08-06$6.32/sh−30,523$193,000→ 22,527,763 total(indirect: By LLC) - Sale
Class A Common Stock
2014-08-07$6.31/sh−66,961$422,845→ 22,460,802 total(indirect: By LLC)
Holdings
- 60,357
Class A Common Stock
- 353,530(indirect: By Spouse)
Class A Common Stock
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on September 11, 2013.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.13 to $6.37, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]S&R Technology Holdings, LLC is wholly owned by Dr. Kuno and her husband. Dr. Kuno disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.02 to $6.41, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.46, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Dr. Kuno disclaims beneficial ownership of the reported securities.
Documents
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeoperating
Related Parties
1- filerCIK 0001365216
Filing Metadata
- Form type
- 4
- Filed
- Aug 6, 8:00 PM ET
- Accepted
- Aug 7, 6:00 PM ET
- Size
- 11.7 KB